Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ,4 ]
Shao, Xiying [1 ,4 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, 1,Banshandong Rd, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4/6; inhibitor; prognostic parameters;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [32] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
    Dalal, Anand A.
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (09) : 1356 - 1367
  • [33] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [34] Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
    Rugo, Hope S.
    Turner, Nicholas C.
    Finn, Richard S.
    Joy, Anil A.
    Verma, Sunil
    Harbeck, Nadia
    Masuda, Norikazu
    Im, Seock-Ah
    Huang, Xin
    Kim, Sindy
    Sun, Wan
    Iyer, Shrividya
    Schnell, Patrick
    Bartlett, Cynthia Huang
    Johnston, Stephen
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 123 - 133
  • [35] HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (06)
  • [36] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: a modified Delphi study
    Geisler, Jurgen
    Karihtala, Peeter
    Tuxen, Malgorzata
    Valachis, Antonis
    Holm, Barbro
    ACTA ONCOLOGICA, 2023, 62 (12) : 1680 - 1688
  • [37] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: A modified Delphi study
    Karihtala, P.
    Valachis, A.
    Tuxen, M.
    Geisler, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S218 - S218
  • [38] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [39] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [40] CLINICAL AND ECONOMIC ANALYSIS OF EFFECTIVENESS OF EVEROLIMUS IN THE TREATMENT OF HR+, HER2-ADVANCED BREAST CANCER IN RUSSIA
    Krasnova, L.
    Vorobiev, P.
    Holownia, M.
    VALUE IN HEALTH, 2014, 17 (07) : A635 - A635
12345